Compounded Semaglutide Cost and Access: A Practical Guide

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

The cost of semaglutide therapy is one of the most consequential variables in whether a patient can stay on the drug long enough to see clinically meaningful results. The published trials show that most of the weight loss benefit accrues in the first 60 to 68 weeks of therapy, with continued benefit on continued therapy and significant regain on discontinuation. A patient who cannot afford to stay on the drug for at least 12 months will not see the full effect. Cost is, in practical terms, a clinical variable.

This page is a plain-language guide to what semaglutide actually costs, what insurance does and does not cover, what compounded semaglutide costs at LegitScript-certified telehealth providers, and what hidden costs patients should plan for. It is not a price comparison and it is not a sales document. It is an attempt to give patients enough information to make a budget that survives contact with reality.

For background on what compounded semaglutide is and the regulatory framework, see the pillar guide.

The Cash Price of Branded Wegovy and Ozempic

The list price for Wegovy in the United States is approximately $1,349 per 28-day supply at the maintenance dose, before insurance. Ozempic carries a similar list price. These prices have been stable for several years. They are set by the manufacturer and apply across pharmacies.

Patients with commercial insurance and a covered indication typically pay between $25 and $200 per month after coverage, depending on the plan. Patients with Medicare cannot use Medicare Part D to cover Wegovy for weight management because federal statute excludes coverage of weight-loss drugs under Part D. This exclusion has been the subject of ongoing legislative debate, but as of mid-2026 it remains in effect. Medicare patients seeking semaglutide for weight management currently pay cash or use commercial-style alternatives. Medicare Part D does cover Ozempic for type 2 diabetes when the patient meets the indication.

Medicaid coverage varies by state. Some state Medicaid programs cover Wegovy for adults meeting obesity criteria, some cover it only for adolescents, and some do not cover it at all. Patients should check their specific state Medicaid formulary.

Manufacturer Patient Assistance and Coupons

Novo Nordisk operates a manufacturer savings program for Wegovy that can reduce out-of-pocket cost for commercially insured patients to as low as $0 per month, with caps on the total annual benefit. Eligibility is restricted to patients with commercial insurance that covers Wegovy. Patients without coverage are not eligible for the standard commercial savings card. Novo Nordisk also operates a patient assistance program for patients meeting income criteria and without other coverage options, but the eligibility threshold is restrictive.

For Ozempic, a similar commercial savings program exists, with similar restrictions to commercially insured patients with coverage.

The practical reality of these programs is that they help patients who already have favorable coverage and do not help patients who do not. The most expensive position to be in is the cash-pay patient without insurance and without eligibility for assistance programs. This is the position from which compounded semaglutide became a relevant option for many patients.

How Compounded Semaglutide Pricing Works

Compounded semaglutide is dispensed by state-licensed 503A pharmacies or FDA-registered 503B outsourcing facilities under individual prescriptions. Pricing is set by the dispensing pharmacy and the telehealth clinic that prescribes the medication. There is no list price because compounded preparations are patient-specific.

Typical pricing at LegitScript-certified telehealth providers ranges from approximately $179 to $399 per month, depending on the dose, the duration of the prescription, the bundled clinical services included, and whether the patient is paying month-to-month or committing to a multi-month plan. Lower starting doses tend to be priced at the lower end of this range and higher maintenance doses at the higher end, because the volume of active ingredient differs.

The pricing structure typically includes the medication itself, the clinical visits required to prescribe and monitor the medication, the pharmacy dispensing fee, and shipping. Some providers bundle ongoing messaging access and clinical support into the monthly price, and some charge separately for asynchronous messaging or additional visits.

The price you see advertised is not always the price you pay. Hidden costs and price changes after the first month are the most common patient complaints in the compounded space. See the section below on hidden costs for what to ask about up front.

What Compounded Semaglutide Actually Costs at HealthRX

For transparency, HealthRX charges a flat monthly rate that includes the medication, the initial clinical evaluation, ongoing clinical support, and shipping. Pricing is published on the membership page and does not change between the first month and subsequent months. The price varies by dose tier in a documented schedule that patients see before they commit.

We do not use introductory pricing that increases after the first month. We do not require multi-month payment up front. Patients can cancel at any time and will not be charged for medication that has not yet shipped.

This is mentioned here not as a sales pitch but because the pricing model is itself a clinical quality signal. A provider that requires three months of payment up front or that doubles the price after the first month is a provider whose business model is structured around patient lock-in, and this often correlates with weaker clinical support after the sale.

For more on how to evaluate telehealth providers, see our cluster hub on compounded GLP-1 telehealth providers.

Hidden Costs to Plan For

Beyond the monthly medication cost, semaglutide therapy involves several other costs that patients often do not anticipate.

Baseline laboratory testing is standard before initiating therapy. Most clinics require a comprehensive metabolic panel, a hemoglobin A1c, a thyroid stimulating hormone test, and sometimes a lipid panel. If you have insurance, these are usually covered with a copay. If you are cash-pay, expect to spend $100 to $300 at a direct-to-consumer lab service depending on the panel.

Periodic follow-up labs are typical at three to six month intervals during therapy. The same cost considerations apply.

Injection supplies, including syringes and alcohol swabs, are usually included with the medication shipment but should be confirmed. Some providers bill these separately.

Sharps disposal is a small but real cost. A FDA-cleared sharps container is required for safe disposal of used syringes and is available at most pharmacies for $5 to $15. Many municipalities also operate free or low-cost sharps disposal programs.

Travel-related costs include the time and cost of medical care if you experience a side effect that requires evaluation outside your home clinic. Most events are mild and managed at home, but emergency department visits for severe dehydration from GI symptoms are not unheard of, and these are not covered by your monthly subscription fee.

For a more detailed walkthrough of the full cost of therapy, see our supporting article on the true monthly cost of semaglutide therapy.

Insurance Coverage Pathways for Compounded Preparations

Compounded medications are generally not covered by commercial insurance plans in the same way as FDA-approved products. Most insurance plans either exclude compounded preparations entirely or require pre-authorization that documents a clinical reason why the FDA-approved product cannot be used.

Some patients with health savings accounts (HSAs) or flexible spending accounts (FSAs) can use these funds toward compounded semaglutide if the prescription is documented for a medical indication. HSA and FSA eligibility is determined by the plan administrator, and patients should keep itemized receipts and a clinical letter on file in case of audit.

The most common path to insurance coverage of GLP-1 therapy is coverage of the branded product (Wegovy or Ozempic) rather than the compounded preparation. For patients with insurance that covers the branded product, that is almost always the cheaper option. Compounded preparations are most cost-relevant for patients without insurance coverage of the branded product.

Cost Per Pound of Weight Loss

A frame that some patients find useful is cost per pound of weight loss. Using the STEP-1 mean of 14.9 percent body weight loss over 68 weeks at the 2.4 mg dose, a 250-pound patient would lose approximately 37 pounds. At a compounded monthly cost of $250, the total drug cost over 68 weeks is approximately $4,000, or roughly $108 per pound of weight lost.

This frame is imperfect because weight loss is not the only outcome of GLP-1 therapy. SELECT showed a 20 percent reduction in major adverse cardiovascular events at the same dose, which is not captured in cost-per-pound analysis. Sleep apnea improvement, knee pain reduction, and metabolic markers also improve in ways that have independent clinical value. But for patients trying to make a budget decision, cost per pound is at least a starting frame that compares directly to bariatric surgery cost per pound, weight-loss program cost per pound, and other interventions in the same space.

Discontinuation and Restart Cost Considerations

The STEP-4 data show that weight regain after semaglutide discontinuation is substantial. Patients who stopped semaglutide after 20 weeks of titration regained 6.9 percent of body weight over the next 48 weeks, while patients who continued lost an additional 7.9 percent. The biological mechanism for regain is well-established: GLP-1 signaling reduces appetite and promotes satiety, and stopping the drug removes that signal.

The cost implication is that semaglutide is, for most patients, a long-term medication. Budgeting only for a six-month course and planning to maintain results without ongoing therapy is not consistent with the published evidence on weight regain. Patients who can only afford a short course of therapy should discuss this with their clinician up front so that the dose, the duration, and the post-discontinuation plan are designed around the budget constraint rather than discovered after the fact.

Some patients use lower-dose or extended-interval maintenance to reduce ongoing cost. This is an off-label approach with limited evidence and should be discussed with the prescribing clinician case by case.

For more on long-term planning, see our cluster hub on long-term and maintenance.

Geographic and State-by-State Access

Compounded semaglutide telehealth providers operate under state-by-state telemedicine and pharmacy regulations. Not every provider is licensed in every state, and not every 503A pharmacy ships to every state. Patients in some states (notably those with the most restrictive telemedicine licensure) have fewer options.

HealthRX is currently licensed in 44 US states. Patients in other states should look for LegitScript-certified providers licensed in their jurisdiction. LegitScript certification is the single most useful starting filter because it verifies pharmacy licensure, clinician licensure, and compliance with state regulations. Providers without LegitScript certification are not necessarily illegitimate, but the absence of certification means the patient is taking on the verification work themselves.

For a guide on how to verify a provider before signing up, see our supporting article on how to verify a telehealth GLP-1 provider.

This hub is part of the Compounded Semaglutide Cost and Access cluster. Related supporting articles include:

For the foundational overview, return to the pillar guide.

Not FDA-approved. HealthRX is not a medical practice. Information on this site is for educational purposes and is not a substitute for individualized medical advice. Treatment decisions are made between you and a licensed clinician. Compounded semaglutide is dispensed by state-licensed 503A pharmacies and FDA-registered 503B outsourcing facilities under individual prescriptions. Pricing referenced is approximate and subject to change. References: STEP-1 (Wilding et al., NEJM 2021), STEP-4 (Rubino et al., JAMA 2021), SELECT (Lincoff et al., NEJM 2023).

This HealthRX guide is educational and is not a prescription, diagnosis, or substitute for care from a licensed clinician. Compounded semaglutide is not FDA-approved. Treatment decisions should be made with a prescriber who has reviewed your medical history.